Recent Developments in Precision Oncology

Researchers from the University of Michigan developed a real-time 3D imaging technique to know precisely where the X-rays hit and how much radiation is delivered when cancer patients receive radiation therapy. With a lack of precision in current imaging, providers could not specifically see which cells in the tumors were targeted by X-rays, leading to both the killing of cancerous cells and some healthy cells. This breakthrough technology could be used to position patients better and adjust the trajectory and the level of radiation to protect healthy cells in the areas surrounding the tumor. The study was published in Nature Biotechnology.

A paper published by authors from multiple National Cancer Institute consortia in the United States and Europe presents the vision of leaders in the oncology field on next-generation precision oncology. The leaders emphasize the importance of developing “3D patient tumor avatars” to allow testing and identifying optimal treatments before applying them to patients. Those “avatars” and their associated data will increase the precision of cancer treatments, reduce the side effects, and improve treatment outcomes. The authors outline the challenges and processes for widespread tumor “avatars” implementation. The study was published in Cancer Cell.

Men Are at Risk for BRCA-associated Cancers

Dr. Robert Sidlow

Dr. Robert Sidlow. Photo by Richard DeWitt.

Jewish people of Ashkenazi (Eastern European) descent have an increased risk of genetic mutations that raise the likelihood of having melanoma, breast, ovarian, pancreatic, and prostate cancers. Yet women are more likely to be screened than men. In a recent Heritage Florida Jewish News article, MSK’s Dr. Robert Sidlow offers guidance to men who may be impacted by these BRCA1 and BRCA2 mutations.

The men Dr. Sidlow sees as director of MSK’s Male BRCA Genetic Risk Program generally make an appointment after a female relative tests positive for a BRCA mutation. He recommends that men who test positive start regular mammograms at age 50 and have clinical breast exams. They should also begin prostate cancer screening at 40, 10 years earlier than the general population.

Learn more about male breast cancer and BRCA genetic mutations.

New Resource: NEJM Journal Watch

The MSK Library now subscribes to NEJM Journal Watch. This resource is for practicing clinicians — physicians, nurses, physician assistants, nurse practitioners, residents, students, pharmacists, and other healthcare professionals – to stay informed and current in their fields. 

The most important research, medical news, drug information, public health alerts, and guidelines across 12 specialties are summarized and put into perspective for you by our team of physician editors. NEJM Journal Watch helps clinicians be clinically prepared with succinct and easy-to-read summaries and expert comments in each issue.